SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceXs quarterly results topped expectations and marked its first profit since its IPO, with rapid growth in its AI-compute business and plans for heavy infrastructure spending driving attention. Many traders welcomed the growth and outlook, while others questioned the valuation, spending and share-unlock risk; discussion of a possible Tesla merger added speculation, but no deal is assured.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micros preliminary first-quarter update sharply raised its revenue and gross-margin outlook, citing stronger AI-platform demand, sparking a surge in shares. Traders largely welcomed the update as evidence of robust AI-server demand and anticipated short covering, while some questioned whether the gains would hold given the companys execution and credibility concerns.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs earnings beat was overshadowed by softer fourth-quarter guidance, slowing revenue growth and a reduced advertising outlook, prompting a sharp selloff. Traders are debating whether the drop reflects worsening growth prospects or an overreaction to the outlook, with some pointing to continued profitability as a reason to buy the dip.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Teslas rebound is drawing attention amid confirmed formation of special committees to explore a potential SpaceX merger, though Musk said a deal is uncertain and would require shareholder support. Traders are split between enthusiasm over possible synergies and skepticism about the terms and timing, while positioning around Teslas Q3 earnings adds volatility.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Q3 earnings expectations dominate, with traders debating whether results and guidance can support Bloom Energys premium valuation after a sharp pullback. Bulls point to fuel-cell demand from AI data centers, while skeptics cite valuation risk and broader weakness in AI-related stocks.

SK hynix, Inc. engages in the design, manufacture, and sale of semiconductor products. Its products include dynamic random access memory, not-AND flash memory, and multi-chip package. The company was founded on October 15, 1949 and is headquartered in Icheon, South Korea.

SK Hynix Inc - ADR

SK Hynix is being swept up in a sharp memory-chip and Korean-market selloff, with traders citing KOSPI weakness, foreign selling, and fears about Chinese competition and the durability of the AI-driven memory cycle. Bulls argue the decline is excessive given strong memory demand and low valuations, while bears see further downside risk from cyclical and oversupply concerns.

Myriad Genetics, Inc. is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. It develops and commercializes molecular tests that help patients and providers uncover genetic insights. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Myriad Genetics, Inc.

Myriads sharp rally is driven mainly by its agreement to sell its prenatal testing business to Labcorp for $210 million in cash plus inventory value, which traders view as a major cash infusion and a shift toward oncology. Bulls see the deal as a balance-sheet and strategic positive, while skeptics argue that selling a revenue-generating unit leaves a smaller business with ongoing debt and execution concerns.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

The FDA accepted CorMedixs REZZAYO filing for priority review for prevention of invasive fungal disease, with a target decision in Q1 2027; traders see the potential label expansion as a major growth opportunity but note that approval is not assured. The community is divided between optimism about the expanded use and frustration that the news has had little effect on the share price, alongside continuing concerns about DefenCaths reimbursement and adoption.

Braze, Inc. operates a customer relationship management platform for mobile applications. Its application combines messaging, audience segmentation, analytics and user support in a single integrated solution. The firm offers push notifications, email, in-app messages, and news feed services. The company was founded by Mark Ghermezian, William Magnuson, and Jonathan Hyman on March 28, 2011 and is headquartered in New York, NY.

Braze Inc - Ordinary Shares - Class A

Braze Inc

Salesforces all-cash agreement to acquire Braze at a substantial premium drove the sharp share-price jump. Traders celebrated the buyout while debating the remaining merger-arbitrage spread and lengthy closing process, with some also weighing analyst downgrades and concerns about the deal valuation.

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Rapport Therapeutics Inc.

Rapport Therapeutics Inc

Rapports RAP-219 Phase 2 trial in acute bipolar mania met its primary and secondary endpoints, prompting a burst of bullish interest. Traders are divided over whether the efficacy is strong enough to outweigh concerns about agitation and higher treatment discontinuations, with the initial rally fading amid profit-taking and short-selling.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AngioDynamics Announces Humana Medicare Advantage Coverage Policy Supporting Broader Access to NanoKnife IRE for Prostate and Liver Cancer

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the bodys vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that Humana has updated its Medicare...

ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/Y

AngioDynamics beats first-quarter earnings estimates as revenues rise 6.9% on strong Med Tech growth, with margin expansion and robust Auryon and NanoKnife sales.

AngioDynamics (ANGO) Q1 2027 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

AngioDynamics Stock Is Falling Thursday: What's Going On?

ANGO stock drops 21% as AngioDynamics reports Q1 results, names Eric Honroth as new CEO, and reaffirms FY27 guidance.read more...

Why AngioDynamics Crashed Today

Key PointsAngioDynamics beat on both top and bottom lines this morning...

AngioDynamics Reiterates FY27 Outlook; Appoints Eric Honroth President And CEO - Update

(RTTNews) - While reporting financial results for the first quarter on Thursday, medical technology company AngioDynamics, Inc. (ANGO) reiterated its adjusted loss and net sales guidance for the full year 2027, based on its first quarter performance and current outlook for the re...

AngioDynamics (ANGO) Reports Q1 Loss, Lags Revenue Estimates

AngioDynamics (ANGO) delivered earnings and revenue surprises of +60.00% and -0.03%, respectively, for the quarter ended August 2026. Do the numbers hold clues to what lies ahead for the stock?

AngioDynamics Inc. Q1 Loss Declines

(RTTNews) - AngioDynamics Inc. (ANGO) announced Loss for first quarter of -$7.10 million...

AngioDynamics Reports Fiscal Year 2027 First Quarter Financial Results; Continued Execution Drives Med Tech Growth and Profitability

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the bodys vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the first quarter...

AngioDynamics Announces Appointment of Eric Honroth as President and Chief Executive Officer

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the bodys vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced the appointment of Eric Honroth as...

AngioDynamics, Inc. is a medical device company, which engages in the development, manufacturing, and sale of medical devices for vascular access, surgery, peripheral vascular disease, and oncology. The firm offers ablation systems, fluid management systems, vascular access, angiographic, drainage, thrombolytic, and venous products. It operates through the Med Tech and Med Device segments. The Med Tech segment consists of technology portfolio including Auryon, the thrombus management platform and NanoKnife. The Med Device segment focuses on core, venous, ports, and other oncology products. The company was founded by Howard S. Stern and Eamonn P. Hobbs on February 9, 1988 and is headquartered in Latham, NY.

Angiodynamic Inc

AngioDynamics Stock Rockets On Upbeat Q3, Improved Full-Year Guidance – But Retail Sentiment Plummets

Equity

Bearish Sentiment

Shares of AngioDynamics, Inc. (ANGO) jumped over 9% on Wednesday after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.angiodynamics.com/news-releases/news-release-details/angiodynamics-reports-fiscal-year-2025-third-quarter-financial">reported</a> upbeat third-quarter earnings along with an improved full-year guidance.For the third quarter of the fiscal year 2025, which ended Feb. 28, 2025, the company reported net sales of $72 million, marking a growth of 9.2% year-on-year and above an analyst estimate of $70.30 million, according to FinChat data.The company reported an adjusted loss per share of $0.08, narrower than an estimated loss of $0.13 per share.AngioDynamics CEO Jim Clemmer said that the company is “well positioned” to deliver profitable growth going forward, thanks to its portfolio strengthened by recent catalysts, including the Food and Drug Administration (FDA) clearance for its NanoKnife System for prostate tissue ablation.“...we're seeing impressive momentum across our MedTech franchise, which grew over 20% for the second quarter in a row, driven by growth within each of our MedTech platform technologies, Auryon, AngioVac, AlphaVac, and NanoKnife. In lock-step with this growth, we continue to improve gross margins and operational efficiency, which allowed us to deliver yet another quarter of positive adjusted EBITDA,” Clemmer said.“With our improved operating leverage and strong balance sheet, we can continue to prudently invest to support high-impact initiatives while remaining on track to hit our fiscal year 2026 profitability targets,” he added.The medical technology company now expects net sales to be in the range of $285 to $288 million for the fiscal year 2025, up from previously issued guidance of $282 to $288 million, owing to increased medical technology net sales.The company expects adjusted earnings before interest, taxes, depreciation, and amortisation (EBITDA) for the year to be $4 to $5 million, an increase from prior guidance of $1 to $3 million.It expects adjusted loss per share in the range of $0.31 to $0.34, an improvement from prior guidance of a loss of $0.34 to $0.38.On Stocktwits, retail sentiment about AngioDynamics dipped from ‘extremely bullish’ to ‘extremely bearish’ territory (21/100), while message volume jumped from ‘high’ to ‘extremely high’ levels over the past 24 hours.<figure class="image"><img style="aspect-ratio:651/154;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_02_at_9_14_19_AM_png_e59baa9145.webp" alt="ANGO's Sentiment Meter and Message Volume as of 9:10 a.m. ET on April 2, 2025 | Source: Stocktwits" width="651" height="154"><figcaption>ANGO's Sentiment Meter and Message Volume as of 9:10 a.m. ET on April 2, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/ANGO">ANGO shares</a> are up by over 15% this year and over 65% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-controlling-shareholder-reports-record-total-income/chf3t4CRbIt">Novo Nordisk’s Controlling Shareholder Novo Holdings Reports Record Total Income, Investment Returns In 2024: Retail Stays Bullish</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

The medical technology company now expects net sales to be $285 to $288 million for the fiscal year 2025, up from previously issued guidance of $282 to $288 million, owing to increased medical technology net sales. 

iShares Russell 2000 ETF

Vanguard Total Stock Market ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

ANGO News